...
首页> 外文期刊>Journal of Hepatology: The Journal of the European Association for the Study of the Liver >Identifying the presence of clinically significant hepatic involvement in hereditary haemorrhagic telangiectasia using a simple clinical scoring index
【24h】

Identifying the presence of clinically significant hepatic involvement in hereditary haemorrhagic telangiectasia using a simple clinical scoring index

机译:使用简单的临床评分指标确定在遗传性出血性毛细血管扩张中是否存在具有临床意义的肝功能

获取原文
获取原文并翻译 | 示例

摘要

Background & Aims Though hepatic involvement is common in patients with hereditary haemorrhagic telangiectasia (HHT), symptomatic liver disease is rare but potentially fatal without liver transplantation. Factors associated with clinically significant liver disease in patients with HHT are unknown. Methods In this prospective cohort study, we included consecutive patients from 2001 to 2011 with definite HHT, who underwent systematic protocol screening including contrast-enhanced hepatic CT and/or abdominal ultrasound. Using a multivariable logistic regression model, we developed a simple clinical scoring index to identify the presence of symptomatic liver disease (cardiac failure, portal hypertension, or biliary disease) or 'at-risk' liver disease (asymptomatic patients, with hepatic bruit, abnormal liver biochemistry, or elevated cardiac index). Results Of 316 patients with definite HHT, 171 patients (54.1%; age 53.4 ± 15.2 y, 101 females) had hepatic involvement on imaging. Twenty-nine patients had symptomatic liver disease (22 patients with high-output heart failure); 45 patients were 'at-risk' for liver disease. Using multivariable logistic regression analysis, we derived a score using age, gender, hemoglobin and alkaline phosphatase at presentation which could accurately distinguish patients with clinically significant liver involvement from patients with no or incidental liver lesions (c-statistic = 0.80). A score <3 indicated low risk (<5%) and score >6 indicated high risk (>80%) of harboring clinically significant liver disease in HHT. Conclusions A simple scoring system can distinguish patients at low, moderate, and high risk of harboring clinically significant liver disease. With validation, this score may be used to identify patients for individualized screening and enrollment in clinical trials.
机译:背景与目的尽管遗传性出血性毛细血管扩张症(HHT)患者常见于肝脏受累,但有症状的肝病很少见,但如果不进行肝移植则可能致命。与HHT患者临床上重要的肝脏疾病相关的因素尚不清楚。方法在这项前瞻性队列研究中,我们纳入了2001年至2011年连续确诊为HHT的患者,这些患者接受了系统的方案筛查,包括造影剂增强型肝CT和/或腹部超声检查。使用多变量logistic回归模型,我们开发了一种简单的临床评分指数来确定是否存在症状性肝病(心力衰竭,门脉高压或胆道疾病)或“高危”肝病(无症状患者,肝淤血,异常)肝脏生化或心脏指数升高)。结果316例明确的HHT患者中,有171例患者(54.1%; 53.4±15.2岁,女性101例)有肝脏受累。 29例有症状性肝病(22例高输出心力衰竭); 45例肝脏疾病处于“高危”状态。使用多变量logistic回归分析,我们得出了使用年龄,性别,血红蛋白和碱性磷酸酶的评分,该评分可以准确地区分具有临床显着肝病的患者和没有或没有肝病灶的患者(c统计量= 0.80)。得分<3表示低风险(<5%),得分> 6表示高风险(> 80%)患有HHT临床上显着的肝病。结论简单的评分系统可以区分具有临床显着肝病风险的低,中和高风险患者。经过验证,该分数可用于识别患者以进行个性化筛查和临床试验。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号